SPPiRE Prescriptions and Potentially Inappropriate Prescribing (PIP) Criteria Study Notes
Overview of SPPiRE Prescriptions and Potentially Inappropriate Prescribing (PIP) Criteria
Source and Basis: The criteria are based on a range of international explicit indicators designed for safer prescribing, specifically utilizing the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) indicators.
Definition of PIP: Potential Inappropriate Prescribing occurs when medications are prescribed in a way that risks outweigh the clinical benefits, or when specific clinical guidelines regarding duration and safety monitoring are not followed.
Focus Areas: The criteria primarily target drug groups frequently associated with preventable drug-related morbidity and drug groups associated with morbidity in the elderly population.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and COX-2 Selective Inhibitors
NSAIDs combined with Diuretics and ACEi/ARB:
Criterion: Prescribing an NSAID simultaneously with a diuretic and an Angiotensin-Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB).
Reason: This combination significantly increases the risk of renal impairment.
NSAIDs in Chronic Kidney Disease:
Criterion: Use in patients with chronic kidney disease where the estimated glomerular filtration rate () is .
Reason: High risk of further renal impairment.
NSAID Duration and Gastroprotection:
Criterion 1: Regular use for a duration of weeks without accompanying gastroprotection.
Criterion 2: Non-COX-2 selective NSAIDs used in patients with a history of Peptic Ulcer Disease (PUD) without gastroprotection.
Criterion 3: NSAIDs used in combination with antiplatelet therapy without gastroprotection.
Reason: These scenarios carry a high risk of Gastro-Intestinal (GI) bleeding.
NSAIDs with Anticoagulants:
Criterion: Concurrent use of an NSAID and an anticoagulant.
Reason: Significant risk of GI bleeding.
NSAIDs in Cardiovascular and Respiratory Conditions:
Criterion: Use in patients with severe hypertension or heart failure.
Reason: Risk of exacerbating hypertension or heart failure symptoms.
COX-2 Selective Inhibitors:
Criterion: Use of COX-2 selective inhibitors in patients with concurrent cardiovascular disease.
Reason: Associated with an increased risk of Myocardial Infarction (MI) or Cerebrovascular Accident (CVA).
Antiplatelet and Anticoagulant Therapy
Antiplatelet Risks:
PUD History: Use in patients with a history of Peptic Ulcer Disease (PUD) without gastroprotection increases the risk of GI bleeding.
Anticoagulant Co-prescription: Use with an anticoagulant without gastroprotection increases the risk of GI bleeding.
Dual Antiplatelet Therapy (DAPT): Use of DAPT without gastroprotection increases GI bleed risk.
PCI Follow-up: The intended duration of treatment for dual antiplatelet therapy should be carefully considered if it exceeds one year post-Percutaneous Coronary Intervention (PCI), as it is usually not indicated beyond this point.
Anticoagulant Duration and Indications:
First Uncomplicated DVT: Anticoagulant use for a duration of months for a first uncomplicated Deep Vein Thrombosis (DVT) is not indicated.
First Uncomplicated PE: Anticoagulant use for a duration of months for a first uncomplicated Pulmonary Embolism (PE) is not indicated.
Direct Oral Anticoagulants (DOACs) and Renal Function:
Dabigatran (Pradaxa): PIP occurs if prescribed when or if renal function is unknown, due to the risk of bleeding.
Rivaroxaban (Xarelto) and Apixaban (Eliquis): PIP occurs if prescribed when or if renal function is unknown, due to the risk of bleeding.
Diuretic Therapy and Monitoring
Safety Monitoring (U&Es):
General Diuretic Monitoring: Prescribing a diuretic with no Urea and Electrolyte (U&E) check in the last weeks is considered PIP due to the risk of renal impairment and electrolyte abnormality.
Combination Diuretics: Use of a loop diuretic and a thiazide diuretic together with no U&E check in the last weeks carries similar risks of renal and electrolyte issues.
Appropriateness of Indication:
Loop Diuretics for Dependent Oedema: Prescribing a loop diuretic solely for dependent oedema in the absence of heart failure, liver failure, or nephrotic syndrome is inappropriate; the risks usually outweigh the benefits.
Thiazide Diuretics and Gout: Use of thiazide diuretics in patients with a history of gout is inappropriate due to the risk of precipitating a gout flare.
Medications Associated with Morbidity in the Elderly
Anticholinergic Drugs and Comorbidities:
High-Risk Conditions: Anticholinergic drugs should be avoided or used with extreme caution in patients with Dementia, Narrow-angle glaucoma, Cardiac conduction abnormalities, or Chronic prostatism, as they can exacerbate these co-morbidities.
Anticholinergic Toxicity: Concomitant use of two or more drugs with anticholinergic properties increases the risk of anticholinergic toxicity.
Specific Antidepressants and Antihistamines:
Tricyclic Antidepressants (TCAs): Should not be used as first-line antidepressants in older patients due to an increased risk of adverse effects and the availability of safer alternatives.
Antimuscarinic Antihistamines: Use is associated with increased morbidity risk in the elderly.
Sedative-Hypnotics (Benzodiazepines and Z-drugs):
Duration: Use for longer than weeks is inappropriate.
Risks: High risk of sedation, confusion, impaired balance, and falls.
Statistical Impact for Insomnia: The Number Needed to Treat () is , while the Number Needed to Harm () is only .
Antipsychotics in Patients with Dementia:
Indication Constraint: Use in patients with dementia who do not have psychosis is inappropriate.
Risks: Associated with an increased risk of stroke.
Usage Guidelines: Should only be used when all other means have failed, at the shortest possible dose for the shortest possible duration.
Miscellaneous Drug Groups and High-Risk Scenarios
Methotrexate Safety:
Frequency: To avoid potentially fatal medication errors, it must be prescribed as a weekly dose.
Strength: Prescribing more than one strength of tablet is considered a high risk for error.
Opioid Management:
Laxative Co-prescription: Regular use of opioids without a laxative is inappropriate due to the high risk of severe constipation.
Corticosteroid Use:
Bone Protection: Use for weeks without bone protection is inappropriate due to the significantly increased risk of fracture.
Proton Pump Inhibitors (PPIs):
Duration: Full therapeutic dose for weeks in cases of uncomplicated PUD or erosive peptic oesophagitis is not indicated.
Metformin in Renal Impairment:
Threshold: Prescription when is inappropriate due to the risk of lactic acidosis.
Abbreviations and Technical Definitions
ACEi: Angiotensin converting enzyme inhibitor
ARB: Aldosterone receptor blocker (also known as Angiotensin II receptor blocker)
COX-2: Cyclooxygenase-2
CVA: Cerebrovascular accident
DVT: Deep vein thrombosis
eGFR: Estimated glomerular filtration rate
GI: Gastro-intestinal
MI: Myocardial infarction
NNH: Number needed to harm
NNT: Number needed to treat
NSAID: Non-steroidal anti-inflammatory drug
PCI: Percutaneous coronary intervention
PE: Pulmonary embolism
PUD: Peptic ulcer disease
U&E: Urea and Electrolytes
Referenced Literature
Dreischulte T, et al. (2012): Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria. BMC clinical pharmacology; 12:5.
O'Mahony D, et al. (2015): STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and ageing; 44(2):213-8.
Clyne B, et al. (2013): Addressing potentially inappropriate prescribing in older patients: development and pilot study of an intervention in primary care (the OPTI-SCRIPT study). BMC health services research; 13:307.
Glass J, et al. (2005): Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Bmj; 331(7526):1169.
Ballard CG, et al. (2006): Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews; (1).